Compare Cronos Group Inc (CRON) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs FMC Corp — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while FMC Corp trades at $8.28 (market cap $1.39B). The key difference: FMC Corp is the larger of the two by market cap, and FMC Corp pays a 3.59% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and FMC Corp for 68 Days on average.
| CRON | FMC | |
|---|---|---|
Market Cap | $1.18B | $1.39B |
Volume | 968,037 | 4,145,979 |
Sector | Health | Basic Materials |
52-Week High | $3.55 | $30.63 |
52-Week Low | $2.30 | $8.44 |
Typical Hold Time | 22 Days | 68 Days |
Enterprise Value | $387.62M | $5.19B |
Dividend Yield | — | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $146.59M in 2025, but net income was -$9.45M. Recent Q2 2026 earnings beat expectations with EPS of $0.09. The company held its first Investor Day in September 2026, highlighting international expansion and cash flow focus.
Outlook is mixed: strong revenue growth and a solid balance sheet with no debt support upside, but profitability remains inconsistent. Risks include cash flow volatility and competitive pressures. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty amid expansion efforts.
FMC trades at $8.36, down 8.03% in the past 24 hours, reflecting bearish technical signals and weak profitability. The company reported a net loss of -$2.24B in 2025, with negative margins and declining revenue. Recent news includes a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227M but driven by financing activities.
The outlook remains challenging due to persistent losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include execution on deleveraging, cyclical industry pressures, and competitive threats. Investment opportunity hinges on successful turnaround efforts and new product approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
